Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses

Authors :: Peter D. Cole
Gérard Michel
Salvatore Buffardi
Alberto Garaventa
Stephen Francis
Richard A. Drachtman
Thomas Manley
Paul Harker-Murray
Thierry Leblanc
Laurence Brugières
Kasey J. Leger
Mariana Sacchi
Maurizio Mascarin
C Mauz-Körholz
Stephen Daw
Auke Beishuizen
Kara M. Kelly
Stacy Cooper
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:S307
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Checkmate
Hematology
Internal medicine
Relapsed refractory
medicine
Classical Hodgkin lymphoma
Early adolescents
Young adult
Nivolumab
Brentuximab vedotin
business
medicine.drug

Full Text Access

Tools